Marianne De Backer is a strategist, scientist, business leader, deal maker, and corporate investor in the healthcare industry. She has more than two decades of experience, and a network that spans across pharmaceutical, biotech, tech, academia, VC, NGO, and government partners worldwide. She has been directly accountable for more than 200 strategic alliances in healthcare, some of which have led to newly approved medicines that are now available to patients. Since 2019, she is a member of the Executive Committee, Executive Vice President and Head of Strategy, Business Development and Licensing of the Bayer AG (BAYRY) Pharmaceuticals division.
Dr. De Backer is spearheading the external innovation growth agenda, resulting in more than 25 new alliances and the acquisitions of Vividion Therapeutics, Noria Therapeutics and PSMA Therapeutics in 2021, and Asklepios Biopharmaceutical and KaNDy Therapeutics in 2020. She serves as a non-executive Director on the boards of Gladstone Foundation, Kronos Bio (KRON) and Arrowhead Pharmaceuticals (ARWR). Marianne holds an MBA from Erasmus University Rotterdam, The Netherlands; Master in Molecular Biology from Vrije Universiteit, Brussels; Master in Engineering Biochemistry and a PhD in Biotechnology, both from Ghent University, Belgium.